Eledon Pharmaceuticals, Inc.

As part of an expert panel at #BIO2025, $ELDN CEO @dalexgros joined leaders from the scientific and medical communities to review key developments across #xenotransplantation and #immunosuppression that are shaping solutions to help address the organ shortage crisis. @IamBiotech

Through @ThePower2Save initiative, @AST_info offers a robust library of educational resources reviewed by #transplantation professionals to support individuals and families at every stage of their #transplant experience. Learn more: myast.org/power2save $ELDN

Our research focuses on the potential to target the CD40L pathway to develop a new approach to #immunosuppression therapy that aims to help address key challenges related to #OrganTransplant function and longevity. Learn more about our science here: eledon.com/science/mechan… $ELDN

In this video, $ELDN CSO Steven Perrin, Ph.D., highlights our approach to advancing innovation in #immunosuppression therapy with the potential to help protect transplanted organs for longer periods of time. Watch the full discussion to learn more: eledon.com/#perrin-interv…

As part of its “Innovation Spotlight” series, @TheScientistLLC connected with $ELDN CSO Steven Perrin, Ph.D., for a discussion exploring key strategies in #immunosuppression therapy and #xenotransplantation to help address challenges in #transplantation: the-scientist.com/extending-tran…

#LivingDonors play a vital role in making lifesaving #OrganDonations possible. For those thinking of becoming a living donor, check out this resource from @UNOSNews offering helpful guidance to support informed decision-making: unos.org/transplant/liv… $ELDN

We’re going live from the @NasdaqExchange Marketsite in New York City! Watch the livestream below to hear from $ELDN CEO @dalexgros during today’s Closing Bell following a successful R&D Day event demonstrating progress toward our mission to achieve #OneTransplantForLife.

Guided by our mission to achieve #OneTransplantForLife, our ongoing Phase 2 BESTOW study is evaluating a potential new approach in #immunosuppression that aims to help prevent rejection in #KidneyTransplantation. Learn more: bestowstudy.com $ELDN

From the first successful human organ #transplant in 1954 to the first #xenotransplant into a living person in 2022, the field of #transplant medicine has been shaped by several groundbreaking milestones. Learn more in this article from #cnnhealth: cnn.com/2025/05/17/hea… $ELDN

As we advance #immunosuppression research for #KidneyTransplant recipients, we recognize the importance of self-advocacy to aid the early detection of #KidneyDisease. Check out @KidneyFund's list of six key steps to help protect #KidneyHealth here: kidneyfund.org/kidney-health-… $ELDN

$ELDN CEO @dalexgros will be participating in an expert panel at #BIO2025 exploring key advances in #xenotransplantation, including our investigational #immunosuppression therapy that aims to help prevent #transplant rejection. Learn more: convention.bio.org/program-1/new-… @IAmBiotech

In this video, $ELDN CSO Steven Perrin, Ph.D., highlights the key role that advances in #immunosuppression and #xenotransplantation play in addressing the organ shortage crisis. For more insights on the future of transplant care, watch the full discussion: eledon.com/#perrin-interv…

Outstanding to see Tim Andrews throw the first pitch at @fenwaypark, just months after receiving a pig kidney #transplant - a groundbreaking procedure we proudly supported with our investigational #immunosuppression therapy #tegoprubart. Watch: wcvb.com/article/man-wh… $ELDN @WCVB

Every #OrganTransplant is a gift, and our goal is to help make that gift last a lifetime. In this @BioTuesdays article, $ELDN CEO @dalexgros shares perspectives on our #immunosuppression research focused on supporting #transplant function and longevity: biotuesdays.com/2025/05/27/ele…